Corporate Events

From July 1, 2026 to September 30, 2026, the company has repurchased 181,900 shares, representing 0.44% for ¥730.04 million. With this, the company has completed the repurchase of 181,900 shares, representing 0.44% for ¥730.04 million under the buyback announced on May 11, 2026.

Kissei Pharmaceutical Co., Ltd. revised consolidated earnings guidance for the Six Months Ending September 30, 2026 and full Fiscal Year Ending March 31, 2027. For the six months, the company now expects net sales of JPY 44,800 million, Operating profit of JPY 500 million, Profit attributable to owners of parent of JPY 7,400 million and Basic earnings per share of JPY 176.92 against previous guidance of net sales of JPY 48,000 million, Operating profit of JPY 1,900 million, Profit attributable to owners of parent of JPY 8,000 million and Basic earnings per share of JPY 196.77. For the Full year, the company now expects net sales of JPY 88,700 million, Operating profit of JPY 2,000 million, Profit attributable to owners of parent of JPY 13,300 million and Basic earnings per share of JPY 326.97 against previous guidance of net sales of JPY 95,700 million, Operating profit of JPY 4,400 million, Profit attributable to owners of parent of JPY 14,500 million and Basic earnings per share of JPY 356.65. Reasons for the Revision: As the sales of TAVNEOS for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis deviated from the planned sales for the first quarter, the Company reduced the sales forecast for the interim period and the full-year period after analyzing the trends of the prescription of TAVNEOS. As for the interim period profit forecast, the Company expects its gross profit to decrease due to an increase in the cost of sales ratio resulting from a decline in the sales of TAVNEOS. Regarding selling, general and administrative expenses, as a result of examining the progress of expenses for the first quarter and the expected expenses for the second quarter, the Company has revised the forecast of operating profit to ¥500 million, down ¥1,400 million (% year on year) from the initial forecast, and the forecast of ordinary profit to ¥1,700 million, down ¥1,100 million (% year on year) from the initial forecast. For extraordinary income, the Company expects to report a gain on sale of investment securities of ¥8,500 million as initially expected and revised the forecast of profit attributable to owners of parent to ¥7,400 million, down ¥600 million (down 4.9% year on year). As for the full-year profit forecast, the Company expects the cost of sales ratio to increase as with the interim period. As for selling, general and administrative expenses, milestone payments resulting from the progress of domestic development of the in-licensed products were initially planned to be recognized in the second half but are now expected to be recognized in the next fiscal year. As a result, the Company has revised the forecast of operating profit to ¥2,000 million, down ¥2,400 million (% year on year) from the initial forecast, and the forecast of ordinary profit to ¥4,000 million, down ¥2,000 million (% year on year) from the initial forecast. For extraordinary income, the Company expects to report a gain on sale of investment securities of ¥14,000 million as initially expected and revised the forecast of profit attributable to owners of parent to ¥13,300 million, down ¥1,200 million (down 3.5% year on year).

Kissei Pharmaceutical Co., Ltd., ¥ 65.0, Cash Dividend, Sep-29-2026

Kissei Pharmaceutical Co., Ltd., ¥ 40.0, Cash Dividend, Sep-29-2026

Kissei Pharmaceutical Co., Ltd. announced the opinion by European authorities regarding concerns over the integrity of data from the international Phase III clinical trial of TAVNEOS (generic name: avacopan), a treatment for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), which are designated as intractable diseases. TAVNEOS was developed by ChemoCentryx and is commercialised outside the US and in selected countries by CSL, its affiliates and partners pursuant to a collaboration and license agreement between Vifor Fresenius Medical Care Renal Pharma Ltd. and ChemoCentryx. Vifor Fresenius Medical Care Renal Pharma Ltd. has subsequently sublicensed the rights in Japan to Kissei. Amgen acquired ChemoCentryx in 2022. On January 30, 2026, the European Medicines Agency (EMA) initiated a review by the Committee for Medicinal Products for Human Use (CHMP) because concerns arose regarding data integrity in the multinational Phase III clinical trial. On June 26, 2026, the CHMP recommended revoking the marketing authorization in the European Union (EU) for TAVNEOS, stating that it had not been demonstrated that the benefits outweigh the risks. The CHMP's opinion has been submitted to the European Commission (EC), and a final decision by the EC is expected later. Kissei will continue the discussions regarding the appropriate measures in Japan with the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency (PMDA). The impact of this matter on Kissei’s business performance is currently under review. If it becomes clear that there will be an impact on our performance, we will promptly disclose the information. TAVNEOS is a treatment for rare diseases in the renal field and others, developed by ChemoCentryx Inc. (USA). This drug is an orally administrable small molecule compound that antagonizes the C5a receptor present on white blood cells such as neutrophils. By inhibiting the migration of white blood cells and the induction of adhesion molecules, it provides a significant and effective therapeutic effect against MPA and GPA.

From May 11, 2026 to June 30, 2026, the company has repurchased 0 shares, representing 0% for ¥0 million. With this, the company has completed the repurchase of 0 shares, representing 0% for ¥0 million under the buyback announced on May 11, 2026.

Kissei Pharmaceutical Co., Ltd., Board Meeting, Jun 23, 2026. Agenda: To consider and approve to dispose of the Company's treasury shares as restricted stock.

Kissei Pharmaceutical Co., Ltd. (Head Office: Matsumoto City, Nagano Prefecture) announced the initiation of information dissemination activities aimed at encouraging healthcare professionals to exercise careful administration of TAVNEOS (generic name: Avacopan), which has been exclusively licensed for development and commercialization in Japan from Vifor Fresenius Medical Care Renal Pharma Ltd. (now CSL Vifor) in June 2017, and has been marketed in Japan since June 2022 for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). On March 31, 2026, the U.S. Food and Drug Administration (FDA) issued a notice warning patients and healthcare professionals about severe drug-induced liver injury identified in patients taking this drug. Furthermore, the Center for Drug Evaluation and Research (CDER) of FDA announced on April 27, 2026, that it proposed the withdrawal of its approval in the United States, asserting that there is new information indicating lack of substantial evidence of effectiveness for the drug and that ChemoCentryx’s application that resulted in FDA approval contained untrue statements of material facts. In addition, the European Medicines Agency (EMA) announced on January 30, 2026, that it has initiated a review by the Committee for Medicinal Products for Human Use (CHMP) due to concerns regarding the integrity of data from the Phase III clinical trial study. Currently, Kissei is gathering detailed information from the U.S. and Europe, providing necessary information to the Pharmaceuticals and Medical Devices Agency (PMDA), and engaging in discussions also with the Ministry of Health, Labour and Welfare. While the approval of this drug in Japan remains in effect, Kissei has begun providing information to healthcare professionals, urging them to refrain from using this drug for new patients and to carefully assess the continuation of treatment for existing patients, explaining the risks of liver dysfunction and alternative treatments to ensure patient safety. Patients currently taking this drug should not independently decide on the continuation of treatment and are advised to consult with their treating physician. The sales revenue of this product for the fiscal year ending March 2026 was JPY 11,524 million. The impact of this matter on Kissei's business performance is currently under review. TAVNEOS, created by ChemoCentryx Inc. (U.S.), is a treatment for rare kidney diseases. It is an orally administered small-molecule agent that antagonizes the C5a receptor on leukocytes, including neutrophils, preventing their migration and the induction of adhesion molecules, thereby exerting therapeutic effects. The indications for this drug, microscopic polyangiitis and granulomatosis with polyangiitis, are designated as intractable inflammatory diseases by the Ministry of Health, Labour and Welfare in Japan and often present with necrotizing glomerulonephritis. ChemoCentryx has licensed the rights to this drug to Vifor Fresenius Medical Care Renal Pharma Ltd. for all countries outside the U.S., and Vifor Fresenius Medical Care Renal Pharma Ltd. has sublicensed the rights in Japan to Kissei. Currently, ChemoCentryx has been acquired by Amgen Inc., and Vifor Fresenius Medical Care Renal Pharma Ltd. has been acquired by CSL Limited. In the U.S., TAVNEOS is marketed by Amgen Inc., and in Europe, it is marketed by CSL Vifor.

Kissei Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Jul 31, 2026

Kissei Pharmaceutical Co., Ltd. reported earnings results for the full year ended March 31, 2026. For the full year, the company reported sales was JPY 97,406 million compared to JPY 88,330 million a year ago. Net income was JPY 13,779 million compared to JPY 11,961 million a year ago. Basic earnings per share from continuing operations was JPY 331.54 compared to JPY 274.21 a year ago.

Kissei Pharmaceutical Co., Ltd. proposed to pay Commemorative Dividend of JPY 40.00 per share for the fiscal year ended March 31, 2026. Scheduled date of general meeting of shareholders is June 23, 2026. Scheduled date of commencing dividend payments is June 24, 2026. For Second Quarter End of Fiscal Year Ending March 31, 2027, the company expects to pay commemorative Dividend of JPY 40.00 per share.

Kissei Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the first half and full year of Fiscal Year Ending March 31, 2027. For the first half, the company expects net sales of JPY 48,000 million, Operating profit of JPY 1,900 million, Profit attributable to owners of parent of JPY 8,000 million and Basic earnings per share of JPY 196.77. For the Full year, the company expects net sales of JPY 95,700 million, Operating profit of JPY 4,400 million, Profit attributable to owners of parent of JPY 14,500 million and Basic earnings per share of JPY 356.65.

Kissei Pharmaceutical Co., Ltd. proposed dividend of JPY 60.00 per share for the Fiscal year ended March 31, 2026 as compared to JPY 55.00 per share paid a year ago. Scheduled date of general meeting of shareholders is June 23, 2026. Scheduled date of commencing dividend payments is June 24, 2026. The Company provided dividend guidance of JPY 65.00 per share for the second quarter end of fiscal year ending March 31, 2027 as compared to JPY 60.00 per share paid a year ago. The Company provided dividend guidance of JPY 65.00 per share for the fiscal year ending March 31, 2027 as compared to JPY 60.00 per share payable to same period prior year.

The Board of Directors of Kissei Pharmaceutical Co., Ltd. has authorized a buyback plan on May 11, 2026.

Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces a share repurchase program. Under the program, the company will repurchase up to 1,300,000 shares, representing 3.14% of its share capital, for ¥ 6,000 million. The company will repurchase its shares in order to implement a flexible capital policy which responds to changes in the business environment, improve capital efficiency, and enhance shareholder returns. The shares repurchased will be cancelled. The program is valid till December 31, 2026. As of April 30, 2026, the company had 41,451,945 shares outstanding (excluding treasury shares) and 5,090,040 shares in treasury.

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.

Kissei Pharmaceutical Co., Ltd., Board Meeting, May 11, 2026. Agenda: To introduce the Restricted Stock Incentive System for the Group Employee Shareholding Association and to dispose of the Company's treasury shares.

Kissei Pharmaceutical Co., Ltd., 2026 Earnings Call, May 13, 2026

Kissei Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 11, 2026

Kissei Pharmaceutical Co., Ltd. announced that it has entered into a sublicense agreement with Orient EuroPharma Co., Ltd. to license development and commercialization rights in Taiwan for the acute myeloid leukemia drug Olutasidenib (generic name), which is being developed by Rigel Pharmaceuticals Inc., which holds global rights following its acquisition of the program from Forma Therapeutics Inc. Under this agreement, Orient EuroPharma Co., Ltd. will develop and commercialize Olutasidenib in Taiwan. Kissei Pharmaceutical Co., Ltd. will receive an upfront payment and milestone payments based on the progress of commercialization in Taiwan, and will supply the formulation to Orient EuroPharma Co., Ltd.

Kissei Pharmaceutical Co., Ltd., Board Meeting, Apr 24, 2026. Agenda: To consider to Announce New President and COO.

Kissei Pharmaceutical Co., Ltd. announced that Yselty tablets 100mg (generic name: Linzagolix choline), which was discovered and developed by Kissei for the treatment of uterine fibroids, has been launched in Japan on March 19, 2026. Yselty is an orally administered GnRH (gonadotropin-releasing hormone) antagonist. It acts by antagonizing GnRH at the GnRH receptor in the pituitary gland and consequently suppressing the secretion of gonadotropins. Ultimately, it reduces the production of estrogen in the ovaries and improves various symptoms of uterine fibroids. In addition, we are also developing the drug in Japan for endometriosis. Overseas, Theramex (U.K.), to which we licensed out the technology, launched the product in Europe in September 2024 under the brand name Yselty for the indication of uterine fibroids, and in November of the same year obtained an additional indication for endometriosis from the European Medicines Agency (EMA). In Taiwan, Synmosa Biopharma (Taiwan) is preparing for the launch. In South Korea and Canada, other companies, to which we have licensed out the technology, are developing Yselty. Uterine fibroids are reported to affect more than 70% of women. They are particularly prevalent among women in their 30s and 40s, who are in the prime of their working lives, and can reduce patients' quality of life (QOL) through excessive menstrual periods and chronic pain symptoms, which also significantly affect their social activities. We have launched a disease awareness website, "be loving" to improve access to medical care for those suffering from uterine fibroids and other female diseases. Through the provision of new treatment options for uterine fibroids and disease awareness activities, we will contribute to the creation of a society in which women can thrive and play an active role. There is no change to our consolidated financial results forecast for the fiscal year ending March 31, 2026. Product Summary of Yselty Tablets 100mg Brand Name Yselty Tablets 100mg Generic Name Linzagolix choline Indications Improvement of the following symptoms based on uterine fibroids Excessive menstrual cycle, lower abdominal pain, back pain, anemia Dosage and Administration The usual adult dosage of Linzagolix is 200mg orally once daily. The first dose should be administered on days 1-5 of the menstrual cycle Formulation Film coated tablets NHI drug price Yselty Tablets 100mg JPY 429.10 Manufacturing and Marketing Authorization Holder Kissei Pharmaceutical Co., Ltd. Date of Marketing Approval in Japan December 22, 2025, Date of NHI drug price standard listing March 18, 2026, Release Date March 19, 2026 Yselty Tablets 100mg.

Kissei Pharmaceutical Co., Ltd., Board Meeting, Feb 27, 2026. Agenda: To consider Disposal of Treasury Shares as Restricted Stock for Employee Shareholding Association.

Kissei Pharmaceutical Co., Ltd. reported earnings results for the nine months ended December 31, 2025. For the nine months, the company reported sales was JPY 72,633 million compared to JPY 65,669 million a year ago. Net income was JPY 11,014 million compared to JPY 8,840 million a year ago. Basic earnings per share from continuing operations was JPY 264.77 compared to JPY 201.4 a year ago.

Kissei Pharmaceutical Co., Ltd. announced that at the Board of Directors meeting held on January 30, 2026, the Company resolved to implement a commemorative dividend as part of the year-end dividend per share for the fiscal year ending March 31, 2026, as well as a commemorative dividend as part of the interim dividend for the fiscal year ending March 31, 2027. The year-end Commemorative dividend of ¥40.00 per share for the fiscal year ending March 31, 2026 is scheduled to be formally determined upon approval at the Board of Directors meeting concerning the financial results to be held in May this year, as well as at the Annual General Meeting of Shareholders scheduled for late June. The company will also pay a commemorative dividend of ¥40 per share as part of the interim dividend for the fiscal year ending March 31, 2027.

Kissei Pharmaceutical Co., Ltd., ¥ 40.0, Cash Dividend, Mar-30-2026

Kissei Pharmaceutical Co., Ltd., Board Meeting, Jan 30, 2026. Agenda: To implement a commemorative dividend as part of the year-end dividend per share for the fiscal year ending March 31, 2026, as well as a commemorative dividend as part of the interim dividend for the fiscal year ending March 31, 2027.

Kissei Pharmaceutical Co., Ltd. expected to report Fiscal Year 2026 results on May 7, 2026. This event was calculated by S&P Global (Created on January 30, 2026).

Kissei Pharmaceutical Co., Ltd. announced that it has received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare for its GnRH antagonist Yselty Tablets 100 mg (generic name: Linzagolix choline), discovered and developed by Kissei, for the indication of uterine fibroids. Yselty is an orally administered GnRH (gonadotropin-releasing hormone) antagonist. Yselty acts by antagonizing GnRH at the GnRH receptor in the pituitary gland and consequently suppressing the secretion of gonadotropins. Ultimately reducing the production of estrogen in the ovaries, and improving various symptoms of uterine fibroids; The company has conducted domestic Phase III clinical trials (KLH2301 and KLH2302) for uterine fibroids, and based on the results of these trials1, the company filed an application for manufacturing and marketing approval for this drug in February 20252. The company also conducting domestic Phase III clinical trials for endometriosis in Japan3. Uterine fibroids are a disease that has been reported to affect more than 70% of women4. It is more common in women in their 30s and 40s, when they are in the prime of their working lives, and can seriously affect patients' quality of life (QOL) and social activities due to excessive menstrual periods and chronic pain symptoms. According to an estimate of economic losses due to women-specific health issues conducted by the Ministry of Economy, Trade and Industry in 2024, the total annual loss of labor productivity due to menstrual complications is estimated at approximately JPY 570 billion, and uterine fibroids are one of the causative diseases. Kissei is preparing for the launch of Yselty with the aim of providing a new treatment option for patients with uterine fibroids, thereby contributing to the creation of a society where women can thrive in good health.

Kissei Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Jan 30, 2026

Kissei Pharmaceutical Co., Ltd., Board Meeting, Dec 01, 2025. Agenda: To consider the Notice of Change to Scheduled Date to Commence Dividend Payments.

Kissei Pharmaceutical Co., Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2026. For the year, the company expects net sales of JPY 95,500 million against previous guidance of JPY 91,500 million, Operating loss of JPY 2,600 million against previous guidance of JPY 4,000 million, Profit attributable to owners of parent of JPY 12,700 million against previous guidance of JPY 12,300 million, Basic earnings per share of JPY 305.56.

Kissei Pharmaceutical Co., Ltd. announced a dividend of JPY 60.00 per share for the second quarter ended September 30, 2025 against JPY 45.00 per share a year ago. Scheduled date of commencing dividend payments is December 3, 2024.

Kissei Pharmaceutical Co., Ltd., ¥ 60.0, Cash Dividend, Mar-30-2026

Kissei Pharmaceutical Co., Ltd. expected to report Q3 2026 results on January 30, 2026. This event was calculated by S&P Global (Created on January 12, 2026).

Kissei Pharmaceutical Co., Ltd., H1 2026 Earnings Call, Nov 06, 2025

Kissei Pharmaceutical Co., Ltd. announced that it has entered into an agreement with Searchlight Pharma, to license development and commercialization rights in Canada for the GnRH antagonist "Linzagolix", which was discovered by Kissei. By executing this agreement, Searchlight will develop and commercialize Linzagolix in Canada. Kissei will receive an upfront payment, milestone payments based on the progress of the development conducted and royalty payments according to the sales of product by Searchlight. Linzagolix is an orally administered GnRH (gonadotropin-releasing hormone) antagonist. Linzagolix acts by antagonizing GnRH at the GnRH receptor in the pituitary gland and consequently suppressing the secretion of gonadotropins. Ultimately reducing the production of estrogen in the ovaries, it is expected to improve the symptoms of uterine fibroids and endometriosis. In Japan, Kissei submitted a new drug application for the indication of uterine fibroid and is currently under regulatory review. Kissei is concurrently conducting a Phase III clinical trial for endometriosis. In overseas, Theramex (UK) launched the product under the brand name "Yselty®?" for the indication of uterine Fibroids in Europe in September 20243. Furthermore, in November of the same year, Theramex received approval from the European Medicines Agency (EMA) for the additional indication of endometriosis. Subsequently, Theramex has been progressing with the launch of the product across various European countries. In Taiwan, Synmosa Biopharmaceuticals (Taiwan) has filed for approval, and in South Korea, JW Pharma (Korea) is currently developing the drug. Kissei is committed to the research and development of new drugs and strives to contribute to the health of people worldwide through collaboration with partner companies.